The Food and Drug Administration has banned e-cigarette maker Juul from selling and distributing its products in the US. It ordered the company to remove its wares from the market or face enforcement actions. Reports earlier this week suggested that an FDA ban on Juul products was imminent. After a two-year review, the agency rejected Juul's application to keep selling tobacco- and menthol-flavored pods, as well as its vape pen. The decision doesn't apply to Juul products that are already in the possession of the company's customers.
Facebook is making steps to clean up its image for underage users, according to a report detailing the company's plans to restrict the sale of tobacco and alcohol on both of its social networks. According to CNN, both Facebook and Instagram plan to prohibit the sale or transfer of tobacco and e-cigarettes on its platform, in addition to placing an 18-years-or-older age restriction on any content related to the sale of tobacco. The policy, which is set to go into effect today, will also apply to posts promoting alcohol. Facebook will be reaching out to the administrators of groups designed to sell tobacco and alcohol to alert them of the change. CNN reports that Facebook will be overseeing the implementation of its new rules through'a combination of technology, human review and reports from our community to find and remove any content that violates these policies,' according to a spokesperson.
Federal health officials on Thursday ordered Juul to pull its electronic cigarettes from the U.S. market, the latest blow to the embattled company widely blamed for sparking a national surge in teen vaping. The action is part of a sweeping effort by the Food and Drug Administration to bring scientific scrutiny to the multibillion-dollar vaping industry after years of regulatory delays. Parents, politicians and anti-tobacco advocates wanted a ban on the devices that many blame for the rise in underage vaping. Supporters say they can help smokers cut back on regular cigarettes. The FDA noted that Juul may have played a "disproportionate″ role in the rise in teen vaping and its application didn't have enough evidence to show that marketing its products "would be appropriate for the protection of the public health."
JUUL has been called'highly addictive', but the firm may be developing a new product that helps users kick the habit once and for all. The San Francisco company filed a patent that describes an artificial intelligence powered product that delivers fewer nicotine amounts to the user by learning their smoking habits over time. The document highlights a device that alternates between nicotine and a non-nicotine product in order to gradually reduce the intake of the drug. The device may also be connected to a smartphone that could log how much nicotine is being consumed, allowing the device to determine how it should regulate the drug, as first reported on by The Logic. JUUL started off as a way of providing the world's one billion smokers with an alternative to combustible tobacco products.
The U.S. Food and Drug Administration (FDA) has permitted the marketing of specific e-cigarette products. This marks the first electronic nicotine delivery system (ENDS) authorization by the agency. The agency announced permission to market e-cigarette products from R.J. Reynolds Vapor Company in a statement Tuesday. With the authorization of the Vuse Solo closed ENDS device and accompanying tobacco-flavored e-liquid pods, specifically Vuse Solo Power Unit, Vuse Replacement Cartridge Original 4.8% G1 and Vuse Replacement Cartridge Original 4.8% G2, the said products are now allowed to be sold in the U.S. Data submitted by the company showed that marketing the products is "appropriate for the protection of public health," the agency said. Mitch Zeller, J.D., the director of the FDA's Center for Tobacco Products, further explained that the tobacco-flavored products could be helpful for "addicted" adult smokers who switch to using the products, whether completely or to reduce their cigarette use. "Today's authorizations are an important step toward ensuring all new tobacco products undergo the FDA's robust, scientific premarket evaluation," Zeller said in the news release.